A 57-year-old, otherwise healthy professional concert singer presents for an elective outpatient prostate biopsy for suspected adenocarcinoma. He has a healthy body mass index (BMI), and physical exam indicates that he would be a grade 1 intubation. He reports that 10 years ago he experienced hoarseness and prolonged throat and mouth pain after intubation for an emergency appendectomy. He concludes this bit of history by volunteering, “I almost sued the guy that jammed that tube down my throat; I couldn’t do my concert dates for two months.” He had surgery for a meningomyocele as an infant (wouldn’t you just know), so a spinal is out. He inquires whether there are any other options. When you suggest a laryngeal mask airway, he replies, “Well, that sounds great, Doc, but are there any drawbacks to having anesthesia with this ‘ellemae’ thing?”
In 1983, Dr. Archie Brain introduced the laryngeal mask airway (LMA) as a device to secure the airway without the use of direct laryngoscopy. By 1988 the LMA became commercially available worldwide, and by 1991 the U.S. Food and Drug Administration had approved its use in the United States. Soon thereafter, the device gained rapid popularity because of its advantages over other options for airway control—namely, direct laryngoscopy with endotracheal intubation or bag-mask ventilation (
Table 15.1). These days, the LMA is an essential piece of equipment on every emergency airway cart and has become nearly ubiquitous in outpatient anesthesia. Despite its many advantages, however, the use of an LMA does carry a small but significant set of risks. Every anesthesia provider should be familiar with these risks—not only to recognize potential complications if they occur, but also to counsel patients properly when requesting informed consent.